Dai Maruyama

Dr. Dai Maruyama

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2015 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
HSH Saito
H Saito
DMDai Maruyama
Dai Maruyama
AMA M Maeshima
A M Maeshima
SMS Makita
S Makita
HKH Kitahara
H Kitahara
KTK Tobinai
K Tobinai
Although bendamustine with or without rituximab has demonstrated remarkable efficacy in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) and mantle cell lymphoma (MCL), 1-3 previous reports showed that the incidence of lymphocytopenia was higher in patients receiving bendamustine with or without rituximab than in those receiving other conventional cytotoxic chemotherapies such as R-CHOP regimen, 4-7 which triggers opportunistic infections including cytomegalovirus (CMV) reactivation, hepatitis B virus reactivation, varicella zoster virus (VZV) infections and Pneumocystis jirovecii pneumonia (PCP). 8-12 However, the duration until recovery of the decreased lymphocytes and CD4-positive T cells to the baseline upon bendamustine treatment is still unclear. 6 We retrospectively analyzed 56 consecutive patients with relapsed or refractory indolent B-NHL and MCL who received bendamustine (Treakisym) with or without rituximab at our institution between 2011 and 2014. The dose of bendamustine in combination with or without rituximab was 90 mg/m 2 /day or 120 mg/m 2 /day on days 1 and 2, respectively. Treatment was given every 28 days for up to six treatment cycles, depending on the response and toxicity. No rituximab maintenance was given. We analyzed their peripheral blood lymphocytes and CD4-positive T-cell counts before, during and after bendamustine treatment, the details of infectious events and their correlations. The study protocol

31 March 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
HKHidetsugu Kawai
Hidetsugu Kawai
KAKiyoshi Ando
Kiyoshi Ando
DMDai Maruyama
Dai Maruyama
KYKazuhito Yamamoto
Kazuhito Yamamoto
EKEiji Kiyohara
Eiji Kiyohara
KTKensei Tobinai
Kensei Tobinai
E7777 is a recombinant cytotoxic fusion protein composed of the diphtheria toxin fragments A and B and human interleukin‐2. It shares an amino acid sequence with denileukin diftitox, but has improved purity and an increased percentage of active monomer. We undertook a multicenter, single‐arm phase II study of E7777 in patients with relapsed or refractory peripheral T‐cell lymphoma (PTCL) and cutaneous T‐cell lymphoma (CTCL) to evaluate its efficacy, safety, pharmacokinetics, and immunogenicity. A total of 37 patients were enrolled, of which 17 and 19 patients had PTCL and CTCL, respectively, and one patient with another type of lymphoma (extranodal natural killer/T‐cell lymphoma, nasal type), diagnosed by the Central Pathological Diagnosis Committee. Among the 36 patients with PTCL and CTCL, objective response rate based on the independent review was 36% (41% and 31%, respectively). The median progression‐free survival was 3.1 months (2.1 months in PTCL and 4.2 months in CTCL). The common adverse events (AEs) observed were increased aspartate aminotransferase (AST) / alanine aminotransferase (ALT), hypoalbuminemia, lymphopenia, and pyrexia. Our results indicated that a 9 µg/kg/d dose of E7777 shows efficacy and a manageable safety profile in Japanese patients with relapsed or refractory PTCL and CTCL, with clinical activity observed across the range of CD25 expression. The common AEs were manageable, but increase in ALT / AST, hypoalbuminemia, and capillary leak syndrome should be carefully managed during the treatment.

7 March 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
DMDai Maruyama
Dai Maruyama
KHKiyohiko Hatake
Kiyohiko Hatake
TKTomohiro Kinoshita
Tomohiro Kinoshita
NFNoriko Fukuhara
Noriko Fukuhara
ICIlseung Choi
Ilseung Choi
KTKensei Tobinai
Kensei Tobinai
Overexpression of programmed death‐1 (PD‐1) ligands contributes to an immunosuppressive microenvironment. Nivolumab is a PD‐1‐blocking antibody that inhibits the PD‐1 pathway and showed good efficacy in several types of malignancy. This phase II study examined the efficacy and safety of nivolumab in 17 Japanese patients with refractory/relapsed classical Hodgkin lymphoma previously treated with brentuximab vedotin. Sixteen patients were included in efficacy analyses and 17 in safety analyses. The primary endpoint was the centrally assessed objective response rate (ORR). The study was commenced in March 2015. We report data obtained at a cutoff of 16 March 2016, at which time 11 patients were still receiving nivolumab. The median (range) duration of treatment and follow‐up were 7.0 (1.4–10.6) months and 9.8 (6.0–11.1) months, respectively. All 17 patients had previously received brentuximab vedotin. The ORR was 81.3% (95% confidence interval [CI]: 54.4–96.0%; 13/16 patients), with complete remission and partial remission in 4 and 9 patients, respectively. The overall survival (OS) and progression‐free survival (PFS) rates at 6 months were 100 and 60.0% (95% CI: 31.8–79.7%), respectively; the median OS and PFS were not reached. The most common adverse events (AE) were pyrexia (41.2%), pruritus (35.3%), rash (35.3%) and hypothyroidism (29.4%). Four patients (23.5%) experienced grade 3 or 4 AE, but most AE were of grade 1 or 2. In conclusion, nivolumab is a potentially effective and tolerable treatment option for Japanese patients with relapsed/refractory classical Hodgkin lymphoma previously treated with brentuximab vedotin.

1 April 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
SMShinichi Makita
Shinichi Makita
AMAkiko Miyagi Maeshima
Akiko Miyagi Maeshima
DMDai Maruyama
Dai Maruyama
KIKoji Izutsu
Koji Izutsu
KTKensei Tobinai
Kensei Tobinai
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articles or submit your research for publishing.

29 June 2017 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
DMDai Maruyama
Dai Maruyama
KTKensei Tobinai
Kensei Tobinai
MOMichinori Ogura
Michinori Ogura
TUToshiki Uchida
Toshiki Uchida
KHKiyohiko Hatake
Kiyohiko Hatake
TOTomoko Ohtsu
Tomoko Ohtsu

5 October 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JNJunko Nomoto
Junko Nomoto
NHNobuhiro Hiramoto
Nobuhiro Hiramoto
MKMotohiro Kato
Motohiro Kato
MSMasashi Sanada
Masashi Sanada
AMAkiko Miyagi Maeshima
Akiko Miyagi Maeshima
YKYukio Kobayashi
Yukio Kobayashi
The TNFAIP3 gene, which encodes a ubiquitin-modifying enzyme (A20) involved in the negative regulation of NF-κB signaling, is frequently inactivated by gene deletions/mutations in a variety of B-cell malignancies. However, the detection of this in primary Hodgkin lymphoma (HL) specimens is hampered by the scarcity of Hodgkin Reed-Sternberg (HR-S) cells even after enrichment by micro-dissection. We used anti-CD30 immunofluorescence with fluorescence in-situ hybridization (FISH) to evaluate the relative number of TNFAIP3/CEP6 double-positive signals in CD30-positive cells. From a total of 47 primary classical Hodgkin lymphoma (cHL) specimens, 44 were evaluable. We found that the relative numbers of TNFAIP3/CD30 cells were distributed among three groups, corresponding to those having homozygous (11%), heterozygous (32%), and no (57%) deletions in TNFAIP3. This shows that TNFAIP3 deletions could be sensitively detected using our chosen methods. Comparing the results with mutation analysis, TNFAIP3 inactivation was shown to have escaped detection in many samples with homozygous deletions. This suggests that TNFAIP3 inactivation in primary cHL specimens might be more frequent than previously reported.